You are here

Thromboresistant vascular grafts:heparin-peptidomimetics

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL077039-01
Agency Tracking Number: HL077039
Amount: $99,750.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2004
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
387 TECHNOLOGY DRIVE SUITE 3119
COLLEGE PARK, MD 20742
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PAUL ZAMORA
 (301) 405-8533
 PZAMORA@BIOSETINC.COM
Business Contact
 LINDA FINN
Phone: (301) 405-8431
Email: LFINN@BIOSETINC.COM
Research Institution
 LOYOLA UNIVERSITY OF CHICAGO
 
Office of Research Services
Illinois, IL 60611
United States

 Nonprofit College or University
Abstract

Thrombosis of synthetic vascular grafts is a major problem with current grafts that necessitates
prophylaxis, can lead to loss of patency with an attendant need for repeat surgery, and comes with a high risk of limb loss. The applicant proposes to develop thromboresistant extended
polytetrafluoroethylene (ePTFE) vascular grafts that use an absorbed coating of heparin to control acute and subacute thrombosis, and also incorporates a bioactive peptidomimetic to encourage endothelialization of the vascular graft surface to reduce chronic loss of patency.
The applicant builds on a platform of in vitro and in vivo studies indicating that the adsorbed heparin coating provides thromboresistance for up to 30 days. The adsorbed heparin coating is a dipcoating and can be easily applied to grafts in a manufacturing setting. To this, the applicant will bring a unique series of peptidomimetics that it has separately developed. The peptidomimetics have been designed to complex to heparin and through that interaction provide a facile manufacturing mode. The applicant will use a series of in vitro and in vivo tests to evaluate the peptidomimetic that provides the highest level of graft endothelialization. Studies will also be
conducted to establish if the peptide/heparin-coated graft can withstand sterilization with ethylene oxide, the preferred sterilization route for ePTFE. It is expected that Phase I studies will lead to the selection of a peptidomimetic(s) to be used in large animal studies of Phase II with the goal of providing durable thromboresistance over a protracted period of time with concomitant
endothelialization of the graft surface.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government